About
Pathos AI applies AI to drug development and is headquartered in New York. It completed a $237 million Series E financing at a post-money valuation of around $3 billion.
Pathos AI applies AI to drug development and is headquartered in New York. It completed a $237 million Series E financing at a post-money valuation of around $3 billion.